• Explore /
  • Poster
  • / NATALEE: Phase III study of ribociclib (RIBO) + endocrine therapy (ET) as adjuvant treatment in hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) early breast cancer (EBC).

NATALEE: Phase III study of ribociclib (RIBO) + endocrine therapy (ET) as adjuvant treatment in hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) early breast cancer (EBC).

Abstract Poster

Authors

null

Dennis J. Slamon

David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA

Dennis J. Slamon , Peter A. Fasching , Ravindranath Patel , Sunil Verma , Sara A. Hurvitz , Stephen K. L. Chia , John Crown , Miguel Martin , Carlos H. Barrios , Gonzalo Spera , Céline Lopez , Inès Hor , Diana Pelov , Gareth Hughes , Moditha Nawinne , Gabriel N. Hortobagyi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Local/Regional/Adjuvant

Track

Breast Cancer

Sub Track

Adjuvant Therapy

Clinical Trial Registration Number

NCT03701334

Citation

J Clin Oncol 37, 2019 (suppl; abstr TPS597)

DOI

10.1200/JCO.2019.37.15_suppl.TPS597

Abstract #

TPS597

Poster Bd #

88b

Abstract Disclosures

Similar Posters

First Author: Yen-Shen Lu

First Author: Michelino DeLaurentiis

First Author: Mario Campone

First Author: Tomás Pascual